Form C/A Waverly Labs Inc

  
    C/A
    
      
        
          0001720044
          XXXXXXXX
        
        020-30269
      
      LIVE
      
        false
        false
        false
      
    
  
  
    
      true
      Issuer is extending campaign end date.
      
        Waverly Labs Inc
        
          Corporation
          DE
          06-16-2014
        
        
          19 MORRIS AVENUE
          BROOKLYN
          NY
          11205
        
        waverlylabs.com
      
      N
      StartEngine Capital, LLC
      0001665160
      007-00007
    
    
      9 percent
      We charge 3% commission paid in equity or securities at the same rate as this offering.
      Other
      Series C Common Stock
      1022
      9.78000
      N/A
      9995.16
      Y
      Other
      At issuer's discretion, with priority given to StartEngine Owners
      1199996.22
      08-01-2022
    
    
      10.00
      1186593.00
      627242.00
      614968.00
      136408.00
      5557.00
      0.00
      490551.00
      889897.00
      496335.00
      101845.00
      832033.00
      423312.00
      631479.00
      348510.00
      0.00
      0.00
      -1246760.00
      -1135320.00
      AL
      AK
      AZ
      AR
      CA
      CO
      CT
      DE
      DC
      FL
      GA
      HI
      ID
      IL
      IN
      IA
      KS
      KY
      LA
      ME
      MD
      MA
      MI
      MN
      MS
      MO
      MT
      NE
      NV
      NH
      NJ
      NM
      NY
      NC
      ND
      OH
      OK
      OR
      PA
      PR
      RI
      SC
      SD
      TN
      TX
      UT
      VT
      VA
      WA
      WV
      WI
      WY
    
    
      
        Waverly Labs Inc
        George Andrew Ochoa
        Chief Executive Officer, Director, Chairman
      
      
        
          George Andrew Ochoa
          Chief Executive Officer, Director, Chairman
          06-30-2022
        
      
    
  

You May Also Be Interested In

• Zealand Pharma Partners with Benchling to Advance R&D of Engineered Peptide Medicines
• Recording of LHV Group's 23 April investor webinar
• Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era